Adding bemotuzumab to chemotherapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether adding a new drug, bemotuzumab, to standard chemotherapy before surgery can help improve outcomes for people with triple-negative breast cancer. It aims to shrink the tumor so that surgery is more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and female.
- You need to have triple-negative breast cancer that has not spread to distant organs.
- You must be willing to receive chemotherapy before surgery and then have surgery.
- You must have a tissue sample available for testing (from a biopsy or surgery).
- You must not have received any prior treatment for this current breast cancer.
- You need to be in generally good health and able to do light activity work.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Neoadjuvant Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.